Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Pfizer (Biosimilars Infliximab Portfolio)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

European Rights of Remicade biosimilar products. The asset is the rights to develop and manufacture the product, infliximab (PF-06438179), which is a tumor necrosis factor alpha (TNF-alpha) inhibitor designed to treat a range of autoimmune diseases, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis and plaque psoriasis.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • 235 East 42nd Street
  • New York, NY 10017
  • United States

Pfizer (Biosimilars Infliximab Portfolio) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Pfizer (Biosimilars Infliximab Portfolio)‘s full profile, request access.

Request full access to PitchBook

Pfizer (Biosimilars Infliximab Portfolio) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Pfizer (Biosimilars Infliximab Portfolio)‘s full profile, request access.

Request full access to PitchBook